1. IL-33 promotes anemia during chronic inflammation by inhibiting differentiation of erythroid progenitors.
- Author
-
Swann JW, Koneva LA, Regan-Komito D, Sansom SN, Powrie F, and Griseri T
- Subjects
- Anemia complications, Animals, Annexin A5 metabolism, Bone Marrow pathology, Chronic Disease, Erythropoiesis, Erythropoietin pharmacology, Hematopoiesis, Inflammation complications, Injections, Interleukin-1 Receptor-Like 1 Protein metabolism, Ki-67 Antigen metabolism, Mice, Inbred BALB C, Mice, Inbred C57BL, Models, Biological, Myelopoiesis, NF-kappa B metabolism, Phosphorylation, Receptors, Erythropoietin metabolism, Signal Transduction, Spondylarthritis pathology, beta-Glucans, Anemia pathology, Cell Differentiation, Erythroid Precursor Cells metabolism, Erythroid Precursor Cells pathology, Inflammation pathology, Interleukin-33 metabolism
- Abstract
An important comorbidity of chronic inflammation is anemia, which may be related to dysregulated activity of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow (BM). Among HSPCs, we found that the receptor for IL-33, ST2, is expressed preferentially and highly on erythroid progenitors. Induction of inflammatory spondyloarthritis in mice increased IL-33 in BM plasma, and IL-33 was required for inflammation-dependent suppression of erythropoiesis in BM. Conversely, administration of IL-33 in healthy mice suppressed erythropoiesis, decreased hemoglobin expression, and caused anemia. Using purified erythroid progenitors in vitro, we show that IL-33 directly inhibited terminal maturation. This effect was dependent on NF-κB activation and associated with altered signaling events downstream of the erythropoietin receptor. Accordingly, IL-33 also suppressed erythropoietin-accelerated erythropoiesis in vivo. These results reveal a role for IL-33 in pathogenesis of anemia during inflammatory disease and define a new target for its treatment., Competing Interests: Disclosures: F. Powrie reported personal fees from GSK, grants from Janssen, personal fees from Genentech, and personal fees from Kintai Therapeutics outside the submitted work. No other disclosures were reported., (© 2020 Swann et al.)
- Published
- 2020
- Full Text
- View/download PDF